Progyny Stock Earnings Reports

Progyny reported a strong start to 2026 with record first-quarter revenue at the high end of expectations and net income, EPS and adjusted EBITDA all above guidance. Member engagement remained healthy with utilization toward the higher end of historical ranges. Management raised full-year expectations for adjusted EBITDA, net income and EPS and provided Q2 guidance that implies sequential growth across key metrics. Sales momentum is positive: pipeline and early commitments are substantially ahead of a year ago, renewals have been materially de‑risked by early favorable notifications from several large clients, and activity with health plan partners (notably Cigna) and aggregators for the Progyny Select offering is encouraging. The company continues to invest in platform capabilities and member experience while maintaining strong margins and cash generation (approximately $225M cash and no debt), completed a $200M repurchase program (≈8.8M shares repurchased, ~$160M in Q1) and is considering a new repurchase authorization. Management reiterated confidence in demand for family-building benefits amid demographic trends (delayed childbearing) and said they see no signs of AI-related or macro-driven reductions in engagement or employer demand. Risks noted include the usual seasonality and potential variability in engagement levels, and forward-looking guidance is based on stated utilization assumptions and excludes material upside from future upsells.